In particular, patients with advanced melanoma have benefited from therapy with monoclonal anti-PD-1 antibodies (nivolumab) or a combination of PD-1 and CTLA-4 (ipilimumab) blockade [7]. This evidence concerns the gene PDCD1 and melanoma.